In the course of the collaboration, Optimata’s researchers will use its proprietary virtual cancer patient software to evaluate preclinical data provided by Eli Lilly. The researchers will suggest ways of optimizing the clinical drug development program through in-silico prediction of the expected response in humans.
Optimata’s virtual patient technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. The technology combines computer models of human physiology, specific diseases and the therapeutic impact of a compound.
The technology forecasts the results of putative preclinical and clinical experiments at an unprecedented scale, allowing an unlimited number of virtual trials to be carried out on a wide range of dosages, treatment schedules and patient population characteristics.
The collaboration will draw upon Optimata’s biomathematical and disease modeling expertise which enables an accurate portrayal of the dynamics of disease processes and detailed predictions of drug effects. The collaboration will demonstrate how using the technology can aid in shortening clinical development time and provide guidance for focused clinical trials.
